SCOTTSDALE, Ariz., April 17, 2009 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX) today announced that the United States Patent and Trademark Office (USPTO) has issued another Notice of Allowance to Medicis for a United States patent application related to SOLODYN(R) in 90mg tablet form. For the week ending April 3, 2009, the 90mg strength represented over 60% of total SOLODYN(R) prescriptions.(1)
